These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772 [TBL] [Abstract][Full Text] [Related]
48. A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Graham L; Banda K; Torres A; Carver BS; Chen Y; Pisano K; Shelkey G; Curley T; Scher HI; Lotan TL; Hsieh AC; Rathkopf DE Invest New Drugs; 2018 Jun; 36(3):458-467. PubMed ID: 29508246 [TBL] [Abstract][Full Text] [Related]
49. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH; Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646 [TBL] [Abstract][Full Text] [Related]
50. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID; BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670 [TBL] [Abstract][Full Text] [Related]
52. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Wei XX; Hsieh AC; Kim W; Friedlander T; Lin AM; Louttit M; Ryan CJ Oncologist; 2017 May; 22(5):503-e43. PubMed ID: 28314838 [TBL] [Abstract][Full Text] [Related]
53. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673 [TBL] [Abstract][Full Text] [Related]
54. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172 [TBL] [Abstract][Full Text] [Related]
55. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer. Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954 [TBL] [Abstract][Full Text] [Related]
57. Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. Zhang T; Kephart J; Bronson E; Anand M; Daly C; Spasojevic I; Bakthavatsalam S; Franz K; Berg H; Karachaliou GS; James OG; Howard L; Halabi S; Harrison MR; Armstrong AJ; George DJ Prostate; 2022 May; 82(7):858-866. PubMed ID: 35286730 [TBL] [Abstract][Full Text] [Related]
58. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis. Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270 [TBL] [Abstract][Full Text] [Related]
59. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Ramalingam S; Humeniuk MS; Hu R; Rasmussen J; Healy P; Wu Y; Harrison MR; Armstrong AJ; George DJ; Zhang T Urol Oncol; 2017 Jun; 35(6):418-424. PubMed ID: 28126272 [TBL] [Abstract][Full Text] [Related]
60. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]